Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.650
Open
1.650
VWAP
1.65
Vol
252.00
Mkt Cap
66.52M
Low
1.650
Amount
415.80
EV/EBITDA(TTM)
--
Total Shares
40.30M
EV
83.42M
EV/OCF(TTM)
--
P/S(TTM)
--
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on using its technology platform for drug discovery and the development of therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.
Show More
Valuation Metrics
The current forward P/E ratio for Beyondspring Inc (BYSI.O) is -5.25, compared to its 5-year average forward P/E of -3.24. For a more detailed relative valuation and DCF analysis to assess Beyondspring Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.24
Current PE
-5.25
Overvalued PE
-0.94
Undervalued PE
-5.54
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.89
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.82
Undervalued EV/EBITDA
-4.60
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
35.18
Current PS
0.34
Overvalued PS
87.95
Undervalued PS
-17.58
Financials
Annual
Quarterly
FY2021Q4
YoY :
+87.78%
338.00K
Total Revenue
FY2021Q4
YoY :
-43.64%
-10.49M
Operating Profit
FY2021Q4
YoY :
-41.62%
-10.73M
Net Income after Tax
FY2021Q4
YoY :
-53.85%
-0.24
EPS - Diluted
FY2021Q4
YoY :
+182.56%
-19.72M
Free Cash Flow
FY2024Q4
N/A
Gross Profit Margin - %
FY2024Q4
N/A
FCF Margin - %
FY2024Q4
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
BYSI News & Events
Events Timeline
2025-03-27 (ET)
2025-03-27
07:11:56
BeyondSpring announces expected 2025 milestones
2025-03-27
07:11:04
BeyondSpring reports FY24 EPS (21c) vs. (34c) last year
2024-11-11 (ET)
2024-11-11
07:19:45
BeyondSpring presents efficacy results from Phase 2 IIT study of plinabulin
Sign Up For More Events
Sign Up For More Events
News
9.5
05-12NewsfilterPinnedBeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
9.0
05-12NASDAQ.COMPinnedBeyondSpring Inc. Reports Positive Early Results for Plinabulin in Metastatic Cancer and Updates on SEED Therapeutics' Progress
9.0
2024-11-11NewsfilterBeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting
Sign Up For More News
People Also Watch
CATX
Perspective Therapeutics Inc
2.700
USD
+7.57%
SRG
Seritage Growth Properties
3.040
USD
+1.67%
ELLO
Ellomay Capital Ltd
15.910
USD
+0.06%
ARAY
Accuray Inc
1.660
USD
0.00%
FUND
Sprott Focus Trust Inc
7.270
USD
0.00%
VUZI
Vuzix Corp
2.400
USD
+14.29%
RDCM
Radcom Ltd
12.380
USD
0.00%
RCEL
AVITA Medical Inc
7.120
USD
-1.79%
LWLG
Lightwave Logic Inc
1.075
USD
+1.42%
RITR
Reitar Logtech Holdings Ltd
3.730
USD
+4.19%
FAQ
What is Beyondspring Inc (BYSI) stock price today?
The current price of BYSI is 1.65 USD — it has increased 0 % in the last trading day.
What is Beyondspring Inc (BYSI)'s business?
What is the price predicton of BYSI Stock?
What is Beyondspring Inc (BYSI)'s revenue for the last quarter?
What is Beyondspring Inc (BYSI)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Beyondspring Inc (BYSI)'s fundamentals?
How many employees does Beyondspring Inc (BYSI). have?